Last reviewed · How we verify

PQP — Competitive Intelligence Brief

PQP (PQP) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Quinolone antimalarial. Area: Infectious Disease.

marketed Quinolone antimalarial Plasmodium DNA gyrase and topoisomerase II Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

PQP (PQP) — Medicines for Malaria Venture. PQP is a quinolone-based antimalarial that inhibits parasite DNA gyrase and topoisomerase II, disrupting DNA replication in Plasmodium species.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PQP TARGET PQP Medicines for Malaria Venture marketed Quinolone antimalarial Plasmodium DNA gyrase and topoisomerase II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Quinolone antimalarial class)

  1. Medicines for Malaria Venture · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PQP — Competitive Intelligence Brief. https://druglandscape.com/ci/pqp. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing